Anti-CD99 monoclonal antibody
Cancer
Discovery/Pre-clinicalProprietary antibody identified
Key Facts
Indication
Cancer
Phase
Discovery/Pre-clinical
Status
Proprietary antibody identified
Company
About Caedo Oncology
Caedo Oncology is an early-stage biotech focused on creating improved cancer treatments through unique immunotherapy approaches that trigger novel, caspase-independent programmed cell death pathways. Founded in 2020 based on research from Oslo University Hospital, the company's proprietary antibodies target cell surface proteins like CD47, CD99, and HLA class I molecules. Its main shareholder is the venture capital fund Sarsia Seed, and it has secured a significant grant from the Norwegian Research Council. The company is led by a team with deep experience in immunology, antibody engineering, and biotech commercialization.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Shared Antigen mRNA Cancer Vaccines | BioNTech | Phase 2 |
| Targeted Oncology Therapies | BioNTech | Phase 1/2 |
| ARGX-119 | Argenx | Phase 1 |
| Oncology Program | Shionogi | Clinical |
| Bmab (Bevacizumab) | Biocon | Approved |
| Ciforadenant (CPI-444) | Corvus Pharmaceuticals | Phase 1/2 |
| Mupadolimab (CPI-006) | Corvus Pharmaceuticals | Phase 1 |
| tovecimig | Compass Therapeutics | Clinical |
| CTX-8371 | Compass Therapeutics | Clinical |
| XmAb 14045 | Xencor | Clinical |
| XmAb 13676 | Xencor | Clinical |
| Vibostolimab | Xencor | Clinical |